A combined fracture and mortality risk index useful fortreatment stratification in hip fragility fractures

Erdem Aras SEZGİN, (Aksaray Üniversitesi, Tıp Fakültesi, Ortopedi ve Travmatoloji Anabilim Dalı, Aksaray, Türkiye)
Ahmet Toygun TOR, (Gazi Üniversitesi, Tıp Fakültesi, Ortopedi ve Travmatoloji Anabilim Dalı, Ankara, Türkiye)
Vetra MARKEVICIUTE, (Litvanya Sağlık Bilimleri Üniversitesi,Ortopedi ve Travmatoloji Bölümü, Litvanya)
Aurimas SIRKA, (Litvanya Sağlık Bilimleri Üniversitesi, Ortopedi ve Travmatoloji Bölümü, Litvanya)
Sarunas TARASEVICIUS, (Litvanya Sağlık Bilimleri Üniversitesi, Ortopedi ve Travmatoloji Bölümü, Litvanya)
Deepak Bushan RAINA, (Lund Üniversitesi, Lund Klinik Bilimler, Ortopedi Bölümü, İsveç)
Yang LİU, (Lund Üniversitesi, Lund Klinik Bilimler, Ortopedi Bölümü, İsveç)
Hanna ISAKSSON, (Lund Üniversitesi, Biyomedikal Mühendisliği Bölümü, İsveç)
Magnus TAGIL, (Lund Üniversitesi, Lund Klinik Bilimler, Ortopedi Bölümü, İsveç)
Lars LIDGREN (Lund Üniversitesi, Lund Klinik Bilimler, Ortopedi Bölümü, İsveç)
Joint diseases and related surgery
3 0
Yıl: 2021 Cilt: 32 Sayı: 3 Sayfa Aralığı: 583 - 589 Metin Dili: İngilizce DOI: 10.52312/jdrs.2021.382 İndeks Tarihi: 29-12-2021

A combined fracture and mortality risk index useful fortreatment stratification in hip fragility fractures

Öz:
Objectives: In this study, we aimed to assess the stratification abilityof the Fracture and Mortality Risk Evaluation (FAME) index forreoperation, new fragility fracture, and mortality during one-yearfollow-up. Patients and methods: Between November 2018 and July 2019,a total of 94 consecutive hip fragility fracture patients fromtwo centers (20 males, 74 females; mean age: 79.3±8.9 years;range, 57 to 100 years) were retrospectively analyzed. The patientswere classified into high, intermediate, and low fracture andmortality risk groups according to the Fracture Risk AssessmentTool (FRAX) score and Sernbo score, respectively, as well asnine combined categories according to the FAME index. Hospitalrecords were reviewed to identify re-fractures (reoperations,implant failure, new fragility fractures on any site) and mortality atone year following the FAME index classification. Results: Overall re-fracture and mortality rates were 20.2% and33%, respectively. High fracture risk category (FRAX-H) wassignificantly associated with higher re-fracture (odds ratio [OR]:2.9, 95% confidence interval [CI]: 1-8.2, p=0.037) and mortalityrates compared to others (OR: 3.7, 95% CI: 1.5-9.3, p=0.003).The patients classified within the FRAX-H category (n=35) haddifferent mortality rates according to their Sernbo classification;i.e., patients classified as low mortality risk (Sernbo-L) (n=17) hadlower mortality rates compared to others in this group (n=18) (35.3%and 66.7%, respectively), indicating a low statistical significance(OR: 0.3, 95% CI: 0.1-1.1, p=0.063). Similarly, within patientsclassified in Sernbo-L category (n=64), those classified as highfracture risk (FRAX-H) (n=17) had significantly higher re-fracturerates compared to others in this group (n=47) (35.3% and 8.5%,respectively), (OR: 5.9; 95% CI: 1.4-24.5), (p=0.017). Multivariatelogistic regression analyses adjusting for covariates (age, sex, lengthof hospital stay and BMI) yielded similar results. Conclusion: The FAME index appears to be a useful stratificationtool for allocating patients in a randomized-controlled trial foraugmentation of hip fragility fractures.
Anahtar Kelime:

Belge Türü: Makale Makale Türü: Diğer Erişim Türü: Erişime Açık
  • 1. Metcalfe D, Judge A, Perry DC, Gabbe B, Zogg CK, Costa ML. Total hip arthroplasty versus hemiarthroplasty for independently mobile older adults with intracapsular hip fractures. BMC Musculoskelet Disord 2019;20:226.
  • 2. Zhao Y, Fu D, Chen K, Li G, Cai Z, Shi Y, et al. Outcome of hemiarthroplasty and total hip replacement for active elderly patients with displaced femoral neck fractures: a meta-analysis of 8 randomized clinical trials. PLoS One 2014;9:e98071.
  • 3. Nherera L, Trueman P, Horner A, Watson T, Johnstone AJ. Comparison of a twin interlocking derotation and compression screw cephalomedullary nail (InterTAN) with a single screw derotation cephalomedullary nail (proximal femoral nail antirotation): a systematic review and metaanalysis for intertrochanteric fractures. J Orthop Surg Res 2018;13:46.
  • 4. Selim A, Ponugoti N, Naqvi AZ, Magill H. Cephalomedullary nailing versus dynamic hip screw with trochanteric stabilisation plate for the treatment of unstable per-trochanteric hip fractures: A meta-analysis. J Orthop Surg Res 2021;16:47.
  • 5. Smith L, Albersheim M, Blaschke BL, Parikh HR, Solfelt DA, Van Heest AE, et al. Trend and economic implications of implant selection in the treatment of intertrochanteric hip fractures: A review of the American Board of Orthopaedic Surgery Database From 2007 to 2017. J Am Acad Orthop Surg 2021;29:789-95.
  • 6. Ekinci Y, Gürbüz K, Batın S, Kahraman M, Doğar F, Kaya Erten Z. A multicenter intertrochanteric fracture study in the elderly: Hemiarthroplasty versus proximal femoral nailing. Jt Dis Relat Surg 2020;31:209-17.
  • 7. Bergström U, Jonsson H, Gustafson Y, Pettersson U, Stenlund H, Svensson O. The hip fracture incidence curve is shifting to the right. Acta Orthop 2009;80:520-4.
  • 8. Williamson S, Landeiro F, McConnell T, Fulford-Smith L, Javaid MK, Judge A, et al. Costs of fragility hip fractures globally: A systematic review and meta-regression analysis. Osteoporos Int 2017;28:2791-800.
  • 9. Hernlund E, Svedbom A, Ivergård M, Compston J, Cooper C, Stenmark J, et al. Osteoporosis in the European Union: medical management, epidemiology and economic burden. A report prepared in collaboration with the International Osteoporosis Foundation (IOF) and the European Federation of Pharmaceutical Industry Associations (EFPIA). Arch Osteoporos 2013;8:136.
  • 10. Dreinhöfer KE, Mitchell PJ, Bégué T, Cooper C, Costa ML, Falaschi P, et al. A global call to action to improve the care of people with fragility fractures. Injury 2018;49:1393-7.
  • 11. Morochovič R, Kňazovický M, Paulo M, Takáčová K, Burda R. Reversed Z-effect and Z-effect phenomena in femoral neck fracture treated with a dynamic locking plate fixation: Case report. Jt Dis Relat Surg 2021;32:249-52.
  • 12. Goodnough LH, Wadhwa H, Tigchelaar SS, DeBaun MR, Chen MJ, Graves ML, et al. Indications for cement augmentation in fixation of geriatric intertrochanteric femur fractures: A systematic review of evidence. Arch Orthop Trauma Surg 2021.
  • 13. Heini PF, Franz T, Fankhauser C, Gasser B, Ganz R. Femoroplasty-augmentation of mechanical properties in the osteoporotic proximal femur: A biomechanical investigation of PMMA reinforcement in cadaver bones. Clin Biomech (Bristol, Avon) 2004;19:506-12.
  • 14. Kok J, Širka A, Grassi L, Raina DB, Tarasevičius Š, Tägil M, et al. Fracture strength of the proximal femur injected with a calcium sulfate/hydroxyapatite bone substitute. Clin Biomech (Bristol, Avon) 2019;63:172-8.
  • 15. Kok J, Širka A, Liu Y, Tarasevičius Š, Belickas J, Tägil M, et al. Augmenting a dynamic hip screw with a calcium sulfate/ hydroxyapatite biomaterial. Med Eng Phys 2021;92:102-9.
  • 16. Širka A, Raina DB, Isaksson H, Tanner KE, Smailys A, Kumar A, et al. Calcium sulphate/hydroxyapatite carrier for bone formation in the femoral neck of osteoporotic rats. Tissue Eng Part A 2018;24:1753-64.
  • 17. Kammerlander C, Neuerburg C, Verlaan JJ, Schmoelz W, Miclau T, Larsson S. The use of augmentation techniques in osteoporotic fracture fixation. Injury 2016;47 Suppl 2:S36-43.
  • 18. Mattsson P, Alberts A, Dahlberg G, Sohlman M, Hyldahl HC, Larsson S. Resorbable cement for the augmentation of internally-fixed unstable trochanteric fractures. A prospective, randomised multicentre study. J Bone Joint Surg [Br] 2005;87:1203-9.
  • 19. Kim SJ, Park HS, Lee DW, Lee JW. Is calcium phosphate augmentation a viable option for osteoporotic hip fractures? Osteoporos Int 2018;29:2021-8.
  • 20. Sezgin EA, Markevičiūtė V, Širka A, Tarasevičius Š, Raina DB, Isaksson H, et al. Combined fracture and mortality risk evaluation for stratifying treatment in hip fracture patients: A feasibility study. Jt Dis Relat Surg 2020;31:163-8.
  • 21. Mellner C, Eisler T, Börsbo J, Brodén C, Morberg P, Mukka S. The Sernbo score predicts 1-year mortality after displaced femoral neck fractures treated with a hip arthroplasty. Acta Orthop 2017;88:402-6.
  • 22. Compston J, Cooper A, Cooper C, et al. UK clinical guideline for the prevention and treatment of osteoporosis. Arch Osteoporos 2017;12:43.
  • 23. Mellner C, Hedström M, Hommel A, Sköldenberg O, Eisler T, Mukka S. The Sernbo score as a predictor of 1-year mortality after hip fracture: a registry study on 55,716 patients. Eur J Trauma Emerg Surg 2020 [Online ahead of print].
  • 24. Roux C, Thomas T, Paccou J, Bizouard G, Crochard A, Toth E, et al. Refracture and mortality following hospitalization for severe osteoporotic fractures: The Fractos Study. JBMR Plus 2021;5:e10507.
  • 25. Bliuc D, Nguyen ND, Nguyen TV, Eisman JA, Center JR. Compound risk of high mortality following osteoporotic fracture and refracture in elderly women and men. J Bone Miner Res 2013;28:2317-24.
  • 26. Stravinskas M, Tarasevicius S, Laukaitis S, Nilsson M, Raina DB, Lidgren L. A ceramic bone substitute containing gentamicin gives good outcome in trochanteric hip fractures treated with dynamic hip screw and in revision of total hip arthroplasty: A case series. BMC Musculoskelet Disord 2018;19:438.
  • 27. Raina DB, Larsson D, Sezgin EA, Isaksson H, Tägil M, Lidgren L. Biomodulation of an implant for enhanced boneimplant anchorage. Acta Biomater 2019;96:619-30.
  • 28. Raina DB, Širka A, Qayoom I, Teotia AK, Liu Y, Tarasevicius S, et al. Long-term response to a bioactive biphasic biomaterial in the femoral neck of osteoporotic Rats. Tissue Eng Part A 2020;26:1042-51.
APA Sezgin E, Tor A, Markeviciute V, Sirka A, Tarasevičius Š, Raina D, Liu Y, Isaksson H, Tägil M, Lidgren L (2021). A combined fracture and mortality risk index useful fortreatment stratification in hip fragility fractures. , 583 - 589. 10.52312/jdrs.2021.382
Chicago Sezgin Erdem Aras,Tor Ahmet Toygun,Markeviciute Vetra,Sirka Aurimas,Tarasevičius Šarūnas,Raina Deepak Bushan,Liu Yang,Isaksson Hanna,Tägil Magnus,Lidgren Lars A combined fracture and mortality risk index useful fortreatment stratification in hip fragility fractures. (2021): 583 - 589. 10.52312/jdrs.2021.382
MLA Sezgin Erdem Aras,Tor Ahmet Toygun,Markeviciute Vetra,Sirka Aurimas,Tarasevičius Šarūnas,Raina Deepak Bushan,Liu Yang,Isaksson Hanna,Tägil Magnus,Lidgren Lars A combined fracture and mortality risk index useful fortreatment stratification in hip fragility fractures. , 2021, ss.583 - 589. 10.52312/jdrs.2021.382
AMA Sezgin E,Tor A,Markeviciute V,Sirka A,Tarasevičius Š,Raina D,Liu Y,Isaksson H,Tägil M,Lidgren L A combined fracture and mortality risk index useful fortreatment stratification in hip fragility fractures. . 2021; 583 - 589. 10.52312/jdrs.2021.382
Vancouver Sezgin E,Tor A,Markeviciute V,Sirka A,Tarasevičius Š,Raina D,Liu Y,Isaksson H,Tägil M,Lidgren L A combined fracture and mortality risk index useful fortreatment stratification in hip fragility fractures. . 2021; 583 - 589. 10.52312/jdrs.2021.382
IEEE Sezgin E,Tor A,Markeviciute V,Sirka A,Tarasevičius Š,Raina D,Liu Y,Isaksson H,Tägil M,Lidgren L "A combined fracture and mortality risk index useful fortreatment stratification in hip fragility fractures." , ss.583 - 589, 2021. 10.52312/jdrs.2021.382
ISNAD Sezgin, Erdem Aras vd. "A combined fracture and mortality risk index useful fortreatment stratification in hip fragility fractures". (2021), 583-589. https://doi.org/10.52312/jdrs.2021.382
APA Sezgin E, Tor A, Markeviciute V, Sirka A, Tarasevičius Š, Raina D, Liu Y, Isaksson H, Tägil M, Lidgren L (2021). A combined fracture and mortality risk index useful fortreatment stratification in hip fragility fractures. Joint diseases and related surgery, 32(3), 583 - 589. 10.52312/jdrs.2021.382
Chicago Sezgin Erdem Aras,Tor Ahmet Toygun,Markeviciute Vetra,Sirka Aurimas,Tarasevičius Šarūnas,Raina Deepak Bushan,Liu Yang,Isaksson Hanna,Tägil Magnus,Lidgren Lars A combined fracture and mortality risk index useful fortreatment stratification in hip fragility fractures. Joint diseases and related surgery 32, no.3 (2021): 583 - 589. 10.52312/jdrs.2021.382
MLA Sezgin Erdem Aras,Tor Ahmet Toygun,Markeviciute Vetra,Sirka Aurimas,Tarasevičius Šarūnas,Raina Deepak Bushan,Liu Yang,Isaksson Hanna,Tägil Magnus,Lidgren Lars A combined fracture and mortality risk index useful fortreatment stratification in hip fragility fractures. Joint diseases and related surgery, vol.32, no.3, 2021, ss.583 - 589. 10.52312/jdrs.2021.382
AMA Sezgin E,Tor A,Markeviciute V,Sirka A,Tarasevičius Š,Raina D,Liu Y,Isaksson H,Tägil M,Lidgren L A combined fracture and mortality risk index useful fortreatment stratification in hip fragility fractures. Joint diseases and related surgery. 2021; 32(3): 583 - 589. 10.52312/jdrs.2021.382
Vancouver Sezgin E,Tor A,Markeviciute V,Sirka A,Tarasevičius Š,Raina D,Liu Y,Isaksson H,Tägil M,Lidgren L A combined fracture and mortality risk index useful fortreatment stratification in hip fragility fractures. Joint diseases and related surgery. 2021; 32(3): 583 - 589. 10.52312/jdrs.2021.382
IEEE Sezgin E,Tor A,Markeviciute V,Sirka A,Tarasevičius Š,Raina D,Liu Y,Isaksson H,Tägil M,Lidgren L "A combined fracture and mortality risk index useful fortreatment stratification in hip fragility fractures." Joint diseases and related surgery, 32, ss.583 - 589, 2021. 10.52312/jdrs.2021.382
ISNAD Sezgin, Erdem Aras vd. "A combined fracture and mortality risk index useful fortreatment stratification in hip fragility fractures". Joint diseases and related surgery 32/3 (2021), 583-589. https://doi.org/10.52312/jdrs.2021.382
Sayfa Oluşturulma Tarihi
23-04-2024 20:51

İLETİŞİM

TÜBİTAK ULAKBİM TR Dizin

Yüzüncüyıl, İşçi Blokları Mahallesi

Muhsin Yazıcıoğlu Caddesi No:51/C

06530 Çankaya / ANKARA +90 (312) 298 92 00

trdizin@tubitak.gov.tr

TÜBİTAK ULAKBİM Ulusal Akademik Ağ ve Bilgi Merkezi Cahit Arf Bilgi Merkezi © Tüm Hakları Saklıdır. Gizlilik Politikası Kullanım Şartları